SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending following news of a major AI partnership with OpenAI, including a chip supply deal and potential equity stake. Community discussions highlight the deal's impact on AMD's competition with Nvidia and its validation of AMD's AI strategy. Traders are watching for continued momentum and potential price targets, while also considering the broader implications for the AI sector.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to reports of potential U.S. government investment in its Greenland rare earth mine, sparking excitement among investors who see it as a strategic national asset. The community is actively discussing the potential for significant gains, comparing it to similar government-backed initiatives in the sector. High trading volume and a low float are contributing to the stock's volatility as traders speculate on upcoming milestones and potential for a short squeeze.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of culture, peace, and digital freedom, emphasizing the project's focus on purpose and long-term growth rather than fleeting hype. Community members highlight the coin's unique appeal, describing it as more than just a token, but a movement towards a more connected and empowered digital future. Discussions also include references to community spaces and the project's website, suggesting active engagement and development within the Weedcoin ecosystem.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the critical minerals sector gains momentum, with community members discussing the potential for a short squeeze and speculating on government support following similar developments with other companies in the space. The stock is nearing its 52-week high, and investors are eyeing key resistance levels with anticipation of NOAA approval news acting as a major catalyst. Community conversations also highlight discussions around chart patterns, potential for further upside, and the long-term vision for deep-sea mining.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power Inc - Ordinary Shares - Class A

SLDP is trending due to a recent surge, with community members actively discussing potential catalysts and the company's strong partnerships. Some investors believe a significant announcement is imminent, while others point to the broader potential of solid-state battery technology and the company's 100% USA battery company status. The community is also debating short squeeze potential and optimal strategies involving shares versus warrants.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending following FDA breakthrough therapy designation for its tralesinidase alfa therapy targeting Sanfilippo Syndrome Type B, a rare genetic disease. Community members are discussing the potential for a significant squeeze given the small float and are speculating about potential price targets, some even suggesting triple-digit gains. The designation is seen as a major catalyst, with some drawing comparisons to other biotech stocks that have experienced similar surges after positive FDA news.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid speculation of a potential partnership with Tesla ($TSLA), fueled by a teaser video featuring Archer's Midnight eVTOL and Tesla's Optimus robot. Community members are closely watching for an official announcement, with some anticipating a short squeeze and significant gains if the rumors prove true, while the company prepares to showcase their technology at an upcoming airshow.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending amid excitement surrounding its upcoming NASDAQ listing and potential short squeeze, with the community actively discussing its undervalued status compared to other quantum computing stocks. Bullish investors are eyeing a significant run, fueled by the company's advancements in quantum-secure stablecoin settlement and potential for major partnerships in the fintech sector. Some traders are closely monitoring short share availability and borrow rates, suggesting a possible squeeze scenario.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as community members discuss the stock's potential, fueled by news of increased Bitcoin production and a new data center acquisition. Bullish sentiment is building, with many believing HIVE is undervalued compared to its peers in the crypto mining and AI infrastructure sectors. Discussions include potential price targets and the company's growth prospects in high-performance computing.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid discussions around its collaboration with NVIDIA and potential for government contracts, fueling both bullish sentiment and skepticism about its valuation. Community members are debating the stock's short squeeze potential and long-term viability, with some pointing to insider selling as a concern. The broader context involves comparisons to other quantum computing stocks and the sector's overall hype.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership,&nbsp;to treat a common viral skin infection.<a href="https://stocktwits.com/symbol/PTHS">Pelthos Therapeutics</a> surged 60.8% to close at $10.01 on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/LGND">Ligand Pharmaceuticals</a> gained 2.1%.The launch triggered a $5 million milestone payment to Ligand under the companies’ license agreement. Under the terms of the licensing deal, Ligand is also entitled to a 13% royalty on worldwide sales of Zelsuvmi and up to $5 million in additional commercial milestones.Ligand also holds a 56% equity stake in Pelthos following the completion of a merger between Pelthos and Channel Therapeutics on July 2.Pelthos announced the merger earlier this month, in which CHRO Merger Sub, a wholly owned subsidiary of Channel, merged with LNHC, a wholly owned subsidiary of Ligand.&nbsp;LNHC survived as a subsidiary of Channel, and the combined company is now operating under the Pelthos Therapeutics name. Concurrent with the merger, Pelthos raised $50.1 million in a private placement led by Murchinson.&nbsp;The investment included new equity as well as the cancellation of $18.8 million in previously advanced bridge capital used to support the commercial launch of Zelsuvmi.Zelsuvmi is a nitric oxide-releasing topical gel approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum,&nbsp;sometimes known commonly as “water warts”, in patients aged one year and older.&nbsp;It is the first prescription medication approved for at-home application by patients, parents, or caregivers. The product was developed using the nitric oxide-based Nitricil platform, now owned by Ligand.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment for both Ligand Pharmaceuticals and Pelthos Therapeutics was ‘bullish’, with ‘high’ message volume for Ligand and ‘extremely high’ activity for Pelthos.Ligand’s stock has gained 15.3%so far in 2025, while Pelthos has surged 266.3% over the same period.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-canada-with-35-tariff-by-august-mulls-blanket-rates-for-others/ch8TD9uR5l4">Trump Threatens Canada With 35% Tariff By August, Mulls Blanket 15-20% Rates For Other Countries</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ligand Pharmaceuticals (LGND) and Pelthos Therapeutics (PTHS) commercially launched Zelsuvmi (berdazimer) topical gel (Photo credit: Getty Images)

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Equity

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.ligand.com/news-and-events/press-releases/news-details/2025/Ligand-Subsidiary-Pelthos-Therapeutics-to-Combine-with-Channel-Therapeutics/default.aspx">entered</a> into a definitive merger agreement with biopharmaceutical firm Ligand Pharmaceuticals Incorporated (LGND).Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc., will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.Channel will acquire 100% of the issued and outstanding equity interests of Pelthos Therapeutics and LNHC, and will change its name to Pelthos Therapeutics Inc.Ligand has agreed to invest $18 million in the combined company, while a group of strategic investors led by Murchinson has agreed to invest $32 million.The transaction is expected to close in the summer of 2025.Once the transaction is completed, the combined company will trade on the NYSE American exchange under the ticker PTHS.Channel, a non-opioid pain treatment therapeutics provider, stated that the combined company will initially focus on accelerating the commercialization of Pelthos’ FDA-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum infections in adults and pediatric patients aged one year and older.Molluscum contagiosum is a poxvirus, afflicting an estimated 16.7 million people in the United States.Ligand will be entitled to a 13% royalty on worldwide sales of Zelsuvmi, the company said.The combined company will also retain Channel’s existing development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks, it added.Channel CEO Frank Knuettel II said that the company performed “extensive due diligence” on the Zelsuvmi market opportunity.“Strategically, it (the merger) provides the potential for near-term revenue generation from an FDA-approved drug, the opportunity to advance Channel’s existing NaV 1.7 programs, and expanded capitalization from strong, long-standing investors,” he said.“This transaction presents a compelling opportunity to launch a commercial-ready product, with significant financial backing from Murchinson, that has the potential to deliver both near and long-term value to our shareholders,” said Ligand CEO Todd Davis.On Stocktwits, retail sentiment around Ligand jumped further into the ‘extremely bullish’ territory over the past 24 hours coupled with a surge in message volume from ‘low’ to ‘extremely high’<figure class="image"><img style="aspect-ratio:648/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_08_AM_png_52226d4e3f.webp" alt="LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits" width="648" height="147"><figcaption>LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LGND">LGND stock</a> is down by about 3% this year but up by over 33% over the past 12 months.Retail sentiment around Channel, meanwhile, jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_44_AM_png_bccf41e1ea.webp" alt="CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits"><figcaption>CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CHRO">CHRO stock</a> is up by about 172% year-to-date but down by nearly 1.5% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lockheed-martin-stock-drops-after-cfo-jay-malave-steps-down-just-days-before-q1-earnings/chQEM9RRbfN">Lockheed Martin Stock Drops After CFO Jay Malave Steps Down Just Days Before Q1 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on...

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual...

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and...

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare...

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update...

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time...

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7...

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

Latest Ratings for LGND
 DateFirmActionFromTo Feb 2022BenchmarkMaintainsBuy Feb 2022BarclaysMaintainsOverweight Sep 2021BarclaysMaintainsOverweight
 View More Analyst Ratings for LGND...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$183.99
Prev Close	$180.99
Open	$182.98
Dividend Yield	0.00%
50-Day Moving Average	$158.31
Beta	0.92
Avg. Volume	232,717.19
PE Ratio	-45.29

52-Week High	$183.81
52-Week Low	$93.58
Market Capitalization	$3.55B
EPS (Annual)	-$0.2204
Price to Book	4.24
Revenue Per Employee	$2.46M
Enterprise Value/EBITDA	N/A

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LGND News

LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B